JP2016503407A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503407A5
JP2016503407A5 JP2015540965A JP2015540965A JP2016503407A5 JP 2016503407 A5 JP2016503407 A5 JP 2016503407A5 JP 2015540965 A JP2015540965 A JP 2015540965A JP 2015540965 A JP2015540965 A JP 2015540965A JP 2016503407 A5 JP2016503407 A5 JP 2016503407A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
tocotrienol
derivative
tocopherol
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540965A
Other languages
English (en)
Japanese (ja)
Other versions
JP6460998B2 (ja
JP2016503407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/001310 external-priority patent/WO2014075135A1/en
Publication of JP2016503407A publication Critical patent/JP2016503407A/ja
Publication of JP2016503407A5 publication Critical patent/JP2016503407A5/ja
Priority to JP2018177662A priority Critical patent/JP6978392B2/ja
Application granted granted Critical
Publication of JP6460998B2 publication Critical patent/JP6460998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540965A 2012-11-13 2013-11-13 トコトリエノールの経粘膜送達 Active JP6460998B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018177662A JP6978392B2 (ja) 2012-11-13 2018-09-21 トコトリエノールの経粘膜送達

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AU2012904937 2012-11-13
AU2012905406 2012-12-11
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018177662A Division JP6978392B2 (ja) 2012-11-13 2018-09-21 トコトリエノールの経粘膜送達

Publications (3)

Publication Number Publication Date
JP2016503407A JP2016503407A (ja) 2016-02-04
JP2016503407A5 true JP2016503407A5 (enExample) 2016-12-28
JP6460998B2 JP6460998B2 (ja) 2019-01-30

Family

ID=50730398

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015540965A Active JP6460998B2 (ja) 2012-11-13 2013-11-13 トコトリエノールの経粘膜送達
JP2018177662A Active JP6978392B2 (ja) 2012-11-13 2018-09-21 トコトリエノールの経粘膜送達
JP2020171008A Pending JP2021008509A (ja) 2012-11-13 2020-10-09 トコトリエノールの経粘膜送達

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018177662A Active JP6978392B2 (ja) 2012-11-13 2018-09-21 トコトリエノールの経粘膜送達
JP2020171008A Pending JP2021008509A (ja) 2012-11-13 2020-10-09 トコトリエノールの経粘膜送達

Country Status (22)

Country Link
US (2) US10675265B2 (enExample)
EP (1) EP2919777B1 (enExample)
JP (3) JP6460998B2 (enExample)
KR (1) KR20150082109A (enExample)
CN (2) CN104582700B (enExample)
AU (1) AU2013344817B2 (enExample)
BR (1) BR112015010703B1 (enExample)
CA (1) CA2891164C (enExample)
DK (1) DK2919777T3 (enExample)
ES (1) ES2778065T3 (enExample)
IL (1) IL238727A0 (enExample)
IN (1) IN2015DN04006A (enExample)
MY (1) MY177940A (enExample)
NZ (1) NZ628963A (enExample)
PE (1) PE20151518A1 (enExample)
PH (1) PH12015501048A1 (enExample)
PL (1) PL2919777T3 (enExample)
PT (1) PT2919777T (enExample)
RU (1) RU2015120181A (enExample)
SG (1) SG11201503640WA (enExample)
WO (1) WO2014075135A1 (enExample)
ZA (1) ZA201504191B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
KR20150082109A (ko) * 2012-11-13 2015-07-15 고다겐 파마슈티컬스 피티와이 엘티디 토코트리에놀의 경점막 전달
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2017025808A1 (en) * 2015-08-11 2017-02-16 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
CN117098556A (zh) * 2020-12-04 2023-11-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543417A1 (en) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP2001342133A (ja) 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
US6864280B2 (en) 2000-03-31 2005-03-08 Eisai Co., Ltd. γ-Tocotrienol-containing diuretics
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
JP4447198B2 (ja) 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びfgf阻害剤並びに食品或いは食品添加物
US6608103B2 (en) * 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
EP1593127B1 (en) 2003-02-14 2012-06-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Radiation protection by gamma-tocotrienol, alpha-tocopherol succinate or gamma-tocopherol succinate
ES2505252T3 (es) 2003-04-10 2014-10-09 Barrie Tan Composiciones de extracto de achiote que incluyen tocotrienoles y tocoferoles y métodos de uso
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
DE602005025339D1 (de) * 2004-05-26 2011-01-27 Kgk Synergize Inc Flavonoide und Tocotrienole enthaltende Zusammensetzungen und deren Verwendungen
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009126866A2 (en) * 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
JP2012531411A (ja) 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ,インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
NO2470168T3 (enExample) * 2009-08-26 2018-06-30
CA2797644A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EA201201374A1 (ru) 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
AU2011323059B2 (en) 2011-02-18 2013-02-21 Biolingus Ip Llc Process for preparing products comprising stabilised actives and compositions comprising same
PT3415139T (pt) * 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
KR20150082109A (ko) * 2012-11-13 2015-07-15 고다겐 파마슈티컬스 피티와이 엘티디 토코트리에놀의 경점막 전달

Similar Documents

Publication Publication Date Title
RU2015120181A (ru) Чресслизистая доставка токотриенола
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2019048843A5 (enExample)
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
WO2010127345A3 (en) Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
JP2012193216A5 (enExample)
JP2014528474A5 (enExample)
JP2015503593A5 (enExample)
JP2010059183A5 (enExample)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
JP2013534228A5 (enExample)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2019507786A5 (enExample)
JP2019524889A5 (enExample)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
EA021395B1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
JP2017508737A5 (enExample)
JP2020522568A5 (enExample)
JP2021091608A5 (enExample)
RU2019110755A (ru) Сублингвальное или буккальное введение dim для лечения заболеваний кожи
JP2017530142A5 (enExample)
JP2016505628A5 (enExample)
EA201590825A1 (ru) Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности